Patient feedback in first-line lung cancer treatment study
Part of Cancer clinical trials.
This study collects patient feedback through questionnaires to see if it helps improve outcomes for people with advanced non-small-cell lung cancer starting chemo-immunotherapy. It may help your care team better understand how you are feeling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have stage IV non-small-cell lung cancer with a PD-L1 level below 50%.
- You have no treatable genetic mutations (no actionable genomic alterations).
- You are about to start or have started your first treatment with chemo-immunotherapy as standard of care.
- You are able to fill out questionnaires (no major neurological conditions that would prevent this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
This trial compares chemotherapy combined with immunotherapy to immunotherapy alone for adults 70 and older with advanced non-small cell lung cancer that has a specific protein level (PD-L1 1-49%). It aims to find which treatment works better for this group.
This study compares two standard treatments for metastatic non-small cell lung cancer when the tumor has low levels of a protein called PD-L1. It looks at how well chemotherapy plus pembrolizumab works versus chemotherapy plus nivolumab and ipilimumab.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
Hear when a new PROMs trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.